|
Found 46 result(s) FROM 1963 pages containing the term 'muscle-derived stem cells'.
Thursday Apr 02, 2009
Hurt Cartilage Harbors Potential OA Cure: Stem Cells
Harnessing the power of chondrogenic progenitor cells in diseased human cartilage may help researchers develop regenerative OA therapies...
Monday Nov 24, 2008
Scleroderma Stem Cell Transplants Advance, Phase III Studies Recruiting Patients
Pilot data on systemic sclerosis (SSc) patients treated with autologous stem cell transplants suggest durable improvements in skin thickening and lung function. Phase III randomized trials are still open to enrollment...
Tuesday Sep 30, 2008
Microparticles May Be Big Players in Systemic Scleroderma Disease Activity
Microparticles—small, membrane, coated vesicles—found in the blood of systemic scleroderma patients might not be inert debris…
Thursday Aug 28, 2008
Mesoblast Reports Preclinical Study Shows Allogeneic Stem Cells in Ewes are Safe, Effective for Cervical Spine Fusion; Therapy May Receive Boost From US FDA’s Recent Alert of Life-Threatening Complications Associated With rhBMP in Cervical Spine Fusions
Mesoblast is currently in phase II clinical trials for fusion of the lumbar spine and, based on these new results, will extend its market opportunity to cover the entire spectrum of spinal fusion. Subject to FDA approval, Mesoblast's therapy will eliminate the need for autograft...
Thursday Aug 21, 2008
Mesoblast Reports Stem Cells Regrow Knee Cartilage in Postmenopausal Ewes With OA; Repair Nonhealing Bones in Humans
Mesoblast, a regenerative medicine company developing treatments for orthopaedic conditions, announced successful preclinical trial results showing that its proprietary adult stem cells regenerated and regrew damaged knee cartilage...
Monday Jun 30, 2008
Preclinical Studies Show that IGF-1-Producing Adult Stem Cells Zoom to Fracture Site, Speed Healing
Preclinical data reported at the 2008 ENDO meeting show that adult stem cell injections might be one approach to treating nonhealing osteoporotic fractures...
Thursday Jun 19, 2008
Stem Cells Might Treat Tough Fractures
Adult stem cells may be the key to healing broken bones that fail to mend properly on their own…
Tuesday Mar 04, 2008
P&G Wins Patent Infringement Lawsuit for Osteoporosis Therapy Actonel®; Teva to Appeal Court Ruling
Procter & Gamble announced that the US District Court of Delaware ruled in its favor in the patent infringement lawsuit the company filed against Teva Pharmaceuticals USA, Inc...
Thursday Feb 28, 2008
Adult Stem Cells Nearing Clinical Use for RA, SLE, Other Autoimmune Diseases
Adult stem cells offer a safer, less controversial approach than embryonic stem cells to treat various rheumatoid and autoimmune diseases, and are now entering randomized clinical trials...
Tuesday Jan 29, 2008
Newer Rheumatoid Arthritis Drugs Lower Production of B Cells
New findings suggest that drugs such as Enbrel®, Humira®, and Remicade® reduce activity of abnormal B-cells, benefiting the patient's immune system...
Thursday Nov 29, 2007
Osiris Announces Clinically and Statistically Significant 1-Year Data From Phase I/II Trial of Chondrogenâ„¢; OA Knee Patients Receive Single Injection of Adult Stem Cells Into Knee
Osiris Therapeutics, Inc, a leading stem cell therapeutic company, announced positive 1-year interim results in the evaluation of Chondrogenâ„¢, a preparation of mesenchymal stem cells obtained from the bone marrow of healthy adult donors and formulated for direct injection into the knee...
Wednesday Oct 31, 2007
Coley Initiates Phase I Study of First-in-Class TLR Antagonist, CPG 52364, for the Treatment of Systemic Lupus Erythematosus
Coley Pharmaceutical Group, Inc, an international biopharmaceutical company having a pipeline of Toll-Like Receptor (TLR) therapeutic product candidates, announced that it has dosed its first subject in a phase I study of its novel, orally-available TLR Therapeutic drug candidate for the treatment of systemic lupus erythematosus (SLE)...
Friday Oct 26, 2007
Rituximab May "Reboot" Immune System in Some Lupus Patients
A subgroup of systemic lupus erythematosus (SLE) patients treated with rituximab to deplete B-cells have delayed recovery of memory B-cells in addition to a prolonged response, suggesting that treatment helps "reboot" the immune system...
Tuesday Aug 28, 2007
Systematic Review Finds No Benefit From Selenium or Vitamins A, C in Arthritis; Raises Methodological Questions About Studies Showing Benefit From Vitamin E
Antioxidant vitamins A, C, and E, sometimes combined with selenium, have been widely touted as beneficial for the treatment of arthritis, but a systematic review finds little convincing evidence of efficacy...
Tuesday Aug 21, 2007
Immunomedics' Epratuzumab Targets Blood B-Cells and Modulates Activation and Proliferation of B-Cells in Lupus Patients
Immunomedics, Inc, a biopharmaceutical company focusing on developing monoclonal antibodies to treat autoimmune diseases and cancer, reported results from a study showing epratuzumab, a humanized monoclonal antibody that targets the CD22 antigen found on peripheral blood B-cells, inhibits the increased activation and proliferation of B-cells in patients suffering from systemic lupus erythematosus (SLE) versus normal subjects...
Thursday Aug 02, 2007
Stem Cell Transplants Offer Hope for Children With Severe, Refractory JIA
Intensive immunosuppression followed by T-cell-depleted autologous hematopoietic stem cell transplantation offers refractory JIA patients a chance for remission, but is it worth the risks?…Brinkman DMC, et al. Arthritis Rheum. 2007;56:2410-2421.
Friday Jun 08, 2007
CCL18 Might Help Monitor Pulmonary Fibrosis in Systemic Sclerosis
Changes in BAL fluid levels of the chemokine CCL18 reflect changes in pulmonary fibrotic activity and might be useful for monitoring disease activity in systemic sclerosis and idiopathic interstitial pneumonias...
Wednesday May 23, 2007
New SLE Treatments Hit B-Cells From Several Directions
Various new treatments directed at B-cells offer mounting interest in SLE arsenal...
Thursday Apr 26, 2007
Cellerant's Allogeneic Hematopoietic Stem Cell Transplants Improve Survival and Disease Symptoms in Lupus Mouse Model
Cellerant Therapeutics Inc, a clinical-stage biotechnology company with a portfolio of products and services under development for the regulation of the hematopoietic system, announced data suggesting that established autoimmune disease can be reversed or stabilized by the transplantation of highly purified allogeneic, hematopoietic adult stem cells (HSC) in a mouse model of systemic lupus erythematosus (SLE)...
Monday Feb 26, 2007
Lupus Patients Clear UV-Damaged "Sunburn Cells" but May Have Unusual Inflammatory Reaction to Them
Sunlight can trigger new skin lesions and worsen disease activity in lupus; this might reflect an abnormal inflammatory response to UV-damaged cells, despite the ability to clear them normally from the epidermis...
Tuesday Feb 20, 2007
Osiris's Chondrogenâ„¢ Adult Stem Cell Therapy Fails to Demonstrate Cartilage Regeneration According to Interim Results from Phase I/II Study
Osiris Therapeutics, a leader in adult stem cell therapy, announced that 6-month interim results from its phase I/II clinical study of Chondrogenâ„¢, a preparation of mesenchymal stem cells obtained from the bone marrow of healthy adult donors and specially formulated for direct injection into the knee for the regeneration of the meniscus in the knee and prevention of osteoarthritis, failed to demonstrate significant amounts of meniscal regeneration...
Tuesday Feb 06, 2007
New RA Vaccine Targets Regulatory T-Cells
A pilot clinical trial of a new RA vaccine derived from autologous synovial T-cells shows proof-of-principle that inducing CD4+ regulatory T-cells can improve clinical and laboratory parameters in RA patients...
Wednesday Jan 10, 2007
Osiris Receives US FDA Fast Track Status for Prochymalâ„¢ Stem Cell Therapy and Clearance to Start Phase III Clinical Trial in Treatment-Resistant Crohn's Disease
Osiris Therapeutics, a leader in adult stem cell therapy, announced that Prochymalâ„¢, a preparation of mesenchymal stem cells obtained from the bone marrow of healthy adult donors and specially formulated for intravenous infusion, has received fast-track designation from the US FDA, expediting the development of the stem cell treatment for Crohn's disease that does not respond to standard therapies.
Thursday Dec 07, 2006
High-Dose Immune Suppression With or Without Stem Cell Transplants For Systemic Sclerosis
Studies are evaluating stem cell transplantation as a potential treatment for autoimmune disease, however, researchers sharply disagree regarding myeloablative vs nonmyeloablative approaches and whether stem cells are really necessary...
Monday Nov 27, 2006
Synovial Cells Predict Response to TNF Inhibitors
The secret to why some RA patients respond to anti-TNF-α drugs and others do not may lie in the synovium…Tak P, et al. Presented at ACR 2006 Meeting.
Tuesday Nov 14, 2006
Non-Myeloablative Stem Cell Transplants Safe, Effective in Scleroderma
A pilot study of a non-myeloablative hematopoietic stem cell transplantation regimen for patients with severe scleroderma reports 90% overall survival and 70% progression-free survival at 2 years…Barr WG, et al. Presented at: ACR 2006 Meeting.
Thursday Nov 02, 2006
Disappointing Results in Study of Stem Cells for Cartilage Repair
Hopes that adult mesenchymal stem cells (MSCs) might be used to create chondrocytes for patching cartilage had a setback when researchers found that culturing them in the usual chondrogenic medium did not produce tissues capable of becoming stable articular cartilage in vivo...
Monday Oct 23, 2006
Osiris Reports Positive Initial Results from Pilot Phase II Study of its Prochymalâ„¢ Stem Cell Therapy in Treatment-Resistant Crohn's Disease
Osiris Therapeutics, a leader in adult stem cell therapy, announced positive results from a pilot 10-patient phase II study using Prochymalâ„¢, an intravenous formulation of mesenchymal stem cells obtained from the bone marrow of healthy volunteer donors, for the treatment of patients with moderate to severe Crohn's disease (CD) who had failed to respond to standard treatments, such as steroids and infliximab (RemicadeR, Centocor, Inc).
Wednesday Sep 27, 2006
UCB, Immunomedic Phase III of Epratuzumab in Patients With Systemic Lupus Erythematosus on Clinical Hold
UCB, SA, licensing partner of Immunomedics, Inc. (Morris Plains, NJ), announced that it has voluntarily, temporarily suspended dosing in the phase III clinical studies of epratuzumab (humanized anti-CD22 antibody) in patients with systemic lupus erythematosus (SLE) because of end-stage manufacturing observations by UCB during a recent routine quality assurance audit of the Immunomedics facilities.
Monday Aug 21, 2006
Osiris IPO Raises $38.5 Million to Advance Mesenchymal Stem Cell Therapies
Osiris Therapeutics, Inc. announced that underwriters sold 3.5 million shares of its common stock at a price of $11.00 per share, achieving the lower end of the targeted share price for its initial public offering and raising $38.5 million.
Tuesday Aug 08, 2006
Geron and University of Edinburgh to Collaborate in Conducting Preclinical Studies with Cell Types Derived from Human Embryonic Stem Cells for Musculoskeletal Applications
Geron Corporation and the University of Edinburgh announced that they have entered into a collaboration to conduct preclinical safety and efficacy studies with three cell types derived from human embryonic stem cells.
Thursday Apr 06, 2006
BMP-6 is a Potent Inducer of Chondrogenesis in Adipose-Derived Adult Stem Cells
Bone morphogenetic protein 6 (BMP-6) stimulates the differentiation of human adipose-derived adult stem (ADAS) cells into cartilage cells... Estes BT, et al. Arthritis Rheum. 2006;54:1222-1232.
Monday Mar 20, 2006
Use of Muscle-Derived Stem Cells May Revolutionize Treatment of OA
Due to their regenerative capabilities, muscle-derived stem cells may one day revolutionize the treatment of osteoarthritis, potentially staving off the need for joint replacement surgery in millions... Huard J, et al. Presented at: 52nd Annual Meeting of the Orthopaedic Research Society; March 18–22, 2006; Chicago, Ill. Workshop 1.
Wednesday Feb 01, 2006
Stem Cell Transplantation Shows Promise in Treatment-Resistant Lupus
Autologous nonmyeloablative hematopoietic stem cell transplantation ameliorates disease activity, improves serologic markers, and stabilizes or reverses organ dysfunction in about half of patients with treatment-refractory systemic lupus erythematosus... Burt RK, et al. JAMA. 2006;295:527-535.
Wednesday Jan 04, 2006
Osiris Raises $19 Million in Private Equity Funding for Adult Stem-Cell Trials
Osiris Therapeutics, Inc, of Baltimore, Maryland, announced that it has closed a $19 million private equity round of financing in support of ongoing clinical trial programs employing its adult mesenchymal stem-cell technology...
Monday Dec 19, 2005
Oral Contraceptives Safe in Systemic Lupus Erythematosus
Taken together, two new prospective studies demonstrate that oral contraceptives (OCs) are safe in women with systemic lupus erythematosus and may represent a paradigm shift in the thinking and clinical practice of rheumatologists who historically have been reluctant to prescribe OCs and other hormones for these patients…Petri M, et al. N Engl J Med. 2005;353:2450-2461; Sánchez-Guerrero J, et al. N Engl J Med. 2005;353:2539-2549.
Friday Nov 04, 2005
Study Provides Additional Clues to the Causes of Systemic Sclerosis and the Potential Efficacy of Paclitaxel
New research in a murine model points to the ability of low-dose paclitaxel (Taxol®) to modulate transforming growth factor-beta (TGF-ß) and lessen fibrosis in systemic sclerosis patients, findings that also provide additional clues to the pathogenesis of the disease... Liu X, et al. PloS Med. 2005;2:e354
Friday Oct 07, 2005
Novel Population of T Cells Found to Produce IL-17; In Vivo Analysis Reveals Role of Cytokine in Inflammatory Disease
New research examining the production and function of the inflammatory cytokine interleukin 17 (IL-17) may pave the way for more effective ways to prevent and treat rheumatoid arthritis (RA) and other autoimmune and inflammatory conditions . . . Nat Immunol [serial online]. October 2, 2005.
Monday Oct 03, 2005
Cytori Therapeutics Reports Differentiation of Adipose-Derived Adult Stem Cells to Spinal Disc
Cytori Therapeutics, Inc, along with its collaborators, released data demonstrating that human adipose-derived adult stem cells have the potential to differentiate into cells with the phenotypic traits and DNA expression markers of mature nucleus pulposus cells...
Tuesday Sep 27, 2005
Mesoblast Limited to Start Human Orthopaedic Trial Using Adult Stem Cell Technology
Mesoblast Limited of Melbourne, Australia, a biotechnology company that develops adult mesenchymal precursor stem cell technology for the regeneration and repair of bone and cartilage, has announced...
Monday Sep 26, 2005
Osiris's Allogeneic Bone Matrix–Containing Stem Cells to Be Distributed by Blackstone Medical
Osiris Therapeutics, Inc, of Baltimore, Maryland, a leader in adult stem-cell therapies that prevent and treat orthopaedic disorders, has signed an agreement...
Thursday Sep 08, 2005
Cyclophosphamide/Stem Cell Transplantation Protocol Shows Promise for Refractory Autoimmune Diseases
Japanese researchers report promising phase I-II trial results showing that high-dose cyclophosphamide supported by autologous peripheral blood stem cell transplantation is feasible and may be effective in the treatment of severe and refractory autoimmune diseases such as systemic sclerosis and SLE...Tsukamoto H, et al. Ann Rheum Dis online August 26, 2005
Monday Aug 29, 2005
Research Clarifies Mechanisms of Self-Tolerance by Natural Killer Cells
New murine research depicting how natural killer cells mature in a healthy immune system may yield clues as to what goes awry in autoimmune disorders. Kim S, et al. Nature. 2005;436:709-713
Tuesday Jul 26, 2005
Systemic Lupus Erythematosus: Is There a Phthalate Connection?
Murine studies suggest that exposure to phthalates may increase susceptibility to SLE and possibly other autoimmune disorders... Lim S-Y and Ghosh SK. J Autoimmun. 2005;25:33-45
Thursday Jun 23, 2005
Rituximab Effective in Central Nervous System Neuropsychiatric Symptoms of Systemic Lupus Erythematosus
New studies suggest growing role for B-cell depletion therapy for the management of select patients with cognitive dysfunction associated with SLE, and may obviate the need for cyclophosphamide or plasmapheresis... Presented at: Annual European Congress of Rheumatology of EULAR; June 8-11, 2005; Vienna, Austria.
Wednesday Dec 22, 2004
UVA-1 Light Useful as Adjuvant Therapy for Systemic Lupus Erythematosus
A new study by Dutch researchers has found that UVA-1 cold light therapy significantly decreases validated disease activity indices in patients with moderately active systemic lupus erythematosus (SLE) without causing significant adverse effects... Polderman MCA, et al. Rheumatology. 2004;43:1402-1404.
|
